NICE recommends Entyvio (vedolizumab) for treatment of Crohn's disease

The National Institute of Health and Care Excellence (NICE) has published final draft guidance endorsing the Entyvio (vedolizumab) from Takeda to treat patients with moderate to severely active Crohn’s disease where treatment with a tumour necrosis factor alpha inhibitor has failed or cannot be tolerated. This decision was a reversal of an earlier decision from NICE that rejected Entyvio on grounds that it was not good value and that the evidence submitted was uncertain.

The draft guidance from NICE states that patients receiving Entyvio for Crohn’s disease should be reassessed after a period of 12 months, and that treatment should only continue if it is still justified as both clinically and cost effective. Final guidance is expected to be published by NICE later this year.